Insight Advisors’s PAVmed PAVM Stock Holding History

Insight Advisors’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-22	Closed	-$56K	–	327
2021 Q3	$56K	Buy	+22	New	+$69.4K	0.02%	311
2021 Q2	–	Sell	-176	Closed	-$362K	–	338
2021 Q1	$362K	Buy	+176	New	+$265K	0.11%	225

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Insight Advisors's PAVM Position: Q4 2021 in Review

Insight Advisors sold out of PAVmed (PAVM) in Q4 2021, closing a stake of 22 shares — an estimated $56K sold.

Insight Advisors first reported a position in PAVM in Q1 2021 and held it in 2 quarters. The position peaked at $362K in Q1 2021. 105 funds tracked by Wall St. Rank hold PAVM as of Q4 2021.

Insight Advisors reported no remaining PAVmed position as of Q4 2021 after selling out during the quarter.
Insight Advisors sold 22 PAVmed shares in Q4 2021, an estimated $56K.
Insight Advisors first reported a position in PAVmed in Q1 2021 and held it in 2 quarters.
Insight Advisors's PAVmed position peaked at $362K in Q1 2021.
105 funds tracked by Wall St. Rank held PAVmed as of Q4 2021.

Based on Insight Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.